

ENDO PHARMACEUTICALS HOLDINGS INC  
 Form 4  
 July 06, 2007

**FORM 4**

UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549

OMB APPROVAL  
 OMB Number: 3235-0287  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
 MANOGUE CAROLINE B

2. Issuer Name and Ticker or Trading Symbol  
 ENDO PHARMACEUTICALS HOLDINGS INC [ENDP]

5. Relationship of Reporting Person(s) to Issuer  
 (Check all applicable)

(Last) (First) (Middle)  
 100 ENDO BOULEVARD  
 (Street)

3. Date of Earliest Transaction (Month/Day/Year)  
 07/03/2007

\_\_\_\_ Director \_\_\_\_\_ 10% Owner  
 Officer (give title below) \_\_\_\_\_ Other (specify below)  
 Exec. V.P., CLO & Secy

CHADDS FORD, PA 19317

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
			Code	V	Amount (A) or (D) Price		
Common Stock, par value \$.01 per share	07/03/2007		M		27,389 A \$ 9.4 0	D	
Common Stock, par value \$.01 per share	07/03/2007		M		32,271 A \$ 9.17 0	D	
Common Stock, par value \$.01 per share	07/03/2007		S		59,660 (1) D \$ 34.9 293,702 (2)	D	

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	Amount or Number of Shares
Stock options granted pursuant to 2000 Stock Incentive Plan	\$ 9.4	07/03/2007		M	27,389	<sup>(3)</sup> 08/08/2011	Common Stock	27,389
Stock options granted pursuant to 2000 Stock Incentive Plan	\$ 9.17	07/03/2007		M	32,271	<sup>(4)</sup> 09/19/2012	Common Stock	32,271

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
MANOGUE CAROLINE B 100 ENDO BOULEVARD CHADDS FORD, PA 19317			Exec. V.P., CLO & Secy	

## Signatures

/s/ Caroline B.  
Manogue

07/06/2007

  \*\*Signature of Reporting  
Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Ms. Manogue had placed 59,660 of the shares underlying her stock options into a 10b5-1 pre-set selling program for a period of approximately 12 months, which began on July 1, 2007 (the "Manogue Pre-Set Selling Program"). The shares sold here were sold pursuant to the Manogue Pre-Set Selling Program, which leaves 0 shares (underlying options) in the Manogue Pre-Set Selling Program.
  - (2) Ms. Manogue's beneficial ownership includes 30,835 shares of Endo common stock and 262,867 shares underlying options granted under the Endo Pharmaceuticals Holdings Inc. 2000 and 2004 Stock Incentive Plans. As of July 6, 2007, 95,194 of these options are exercisable.
  - (3) Of these 27,389 stock options, 6,847 were exercisable on August 8, 2002, 6,847 were exercisable on August 8, 2003, 6,847 were exercisable on August 8, 2004 and 6,848 were exercisable on August 8, 2005.
  - (4) Of these 32,271 stock options, 8,067 were exercisable on September 19, 2003, 8,068 were exercisable on September 19, 2004, 8,068 were exercisable on September 19, 2005 and 8,068 were exercisable on September 19, 2006.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.